Returning investor GV returned for a round which hiked the clinical data software provider's overall funding to over $470m.
DNAnexus, a US-based provider of biomedical data analysis software, raised $200m in funding from investors including GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, yesterday. Alternative investment firm Blackstone’s Growth fund led the round, which also featured Perceptive Advisors, Innovatus Capital Partners, Foresite Capital and Northpond Ventures. Founded in 2009, DNAnexus operates…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
